육종 치료제 시장 : 시장 규모, 점유율, 성장률, 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of sarcoma drugs Market

The global sarcoma drugs market is witnessing steady expansion driven by increasing demand for advanced and effective therapies for rare and complex sarcoma subtypes. According to the report, the global sarcoma drugs market size was valued at USD 2.98 billion in 2025. The market is projected to reach USD 3.26 billion in 2026 and is expected to grow to USD 6.22 billion by 2034, exhibiting a CAGR of 8.41% during the forecast period. In 2025, North America dominated the market with a share of 47.65%, supported by strong oncology infrastructure, early adoption of innovative therapies, and higher access to rare cancer treatment centers.

Sarcoma drugs refer to therapeutic products used for the treatment of sarcomas, which are a group of rare cancers originating in connective tissues such as bone, muscle, fat, and blood vessels. Due to high disease heterogeneity and multiple histological subtypes, treatment requires targeted, precision-based, and subtype-specific drug approaches including tyrosine kinase inhibitors, immunotherapies, chemotherapy agents, and emerging cell therapies.

MARKET DEFINITION AND SCOPE

The sarcoma drugs market covers a wide range of therapeutic options used across different sarcoma types such as gastrointestinal stromal tumors (GIST), liposarcoma, leiomyosarcoma, synovial sarcoma, osteosarcoma, and desmoid tumors. The scope includes branded and generic drugs administered through oral and parenteral routes in hospital pharmacies, retail pharmacies, and online pharmacies.

The market also includes increasing adoption of precision oncology approaches, biomarker-driven therapies, and orphan drug development programs targeting rare sarcoma populations. Growing clinical research activity and regulatory support for rare diseases are expanding the development pipeline and strengthening long-term market potential.

MARKET DYNAMICS

DRIVERS

A major driver of the sarcoma drugs market is the rising unmet medical need for rare and advanced sarcoma subtypes. Many patients with relapsed or metastatic sarcoma have limited treatment options, increasing demand for novel targeted therapies. Pharmaceutical companies are investing heavily in precision oncology and subtype-specific drug development to improve survival outcomes.

Another key driver is strong regulatory support for orphan drugs and rare cancer therapies. Fast-track approvals and orphan drug designations are encouraging companies to accelerate clinical trials and bring innovative therapies to market more efficiently. For instance, drugs like LP-284 and tazemetostat have received orphan designations, supporting market expansion.

TRENDS

A significant trend in the market is the shift toward histology-specific and biomarker-driven therapies. Companies are increasingly focusing on genetically defined sarcoma subtypes to improve treatment accuracy and clinical outcomes. Cell therapies and targeted therapies are also gaining traction in late-stage development pipelines.

RESTRAINTS

The major restraint in the market is the highly fragmented and rare nature of sarcoma diseases. With less than 1% of total cancer cases globally, patient recruitment for clinical trials is limited, increasing development time and cost. Small patient populations also restrict large-scale commercial returns, limiting investment in some sarcoma subtypes.

SEGMENTATION ANALYSIS

By drug class, tyrosine kinase inhibitors dominate the market due to their wide clinical usage in GIST and other sarcoma-related indications. Drugs such as imatinib continue to maintain strong market presence due to long-standing treatment adoption.

By disease indication, gastrointestinal stromal tumors (GIST) hold the largest share due to multiple approved targeted therapies and higher treatment continuity compared to other sarcoma types.

By age group, the adult segment dominates the market as most approved therapies are indicated for adult patients with advanced or metastatic disease.

By route of administration, the oral segment leads the market due to convenience, long-term treatment suitability, and strong presence of oral targeted therapies.

By distribution channel, hospital pharmacies dominate due to centralized cancer care and specialist treatment requirements.

REGIONAL INSIGHTS

North America leads the global market due to strong healthcare infrastructure and early adoption of innovative oncology drugs. Europe follows with steady growth supported by orphan drug approvals and rare cancer programs. Asia Pacific is expanding due to improving oncology access and regulatory support in countries like Japan and China. Latin America and the Middle East & Africa are witnessing gradual growth driven by improving healthcare systems and rising cancer awareness.

COMPETITIVE LANDSCAPE

The market is moderately consolidated with key players including Novartis AG, Pfizer Inc., Deciphera Pharmaceuticals, Blueprint Medicines Corporation, Eisai Co., Ltd., and Adaptimmune Therapeutics plc. These companies are focusing on pipeline expansion, strategic collaborations, and targeted therapy development to strengthen market position.

REPORT COVERAGE

This report covers global sarcoma drugs market size for 2025, 2026, and 2034 along with detailed analysis of growth drivers, trends, restraints, segmentation by drug type, indication, age group, distribution channel, and regional outlook. It also highlights competitive landscape and recent industry developments shaping the market.

CONCLUSION

The global sarcoma drugs market is projected to grow from USD 2.98 billion in 2025 to USD 3.26 billion in 2026 and reach USD 6.22 billion by 2034. Rising demand for precision oncology, increasing orphan drug approvals, and growing focus on rare cancer therapies will continue to drive long-term market expansion.

Segmentation By Drug, Drug Class, Disease Indication, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Region

By Drug * Imatinib

• Pazopanib
• Ripretinib
• Nirogacestat
• Trabectedin
• Avapritinib
• Others

By Drug Class * Cytotoxic Chemotherapy

• Tyrosine Kinase Inhibitors (TKIs)
• Gamma Secretase Inhibitors
• Immune Checkpoint Inhibitors
• Cell Therapies
• Epigenetic/EZH2 Inhibitors
• Others

By Disease Indication * Gastrointestinal Stromal Tumor (GIST)

• Leiomyosarcoma
• Liposarcoma
• Synovial Sarcoma
• Desmoid Tumors
• Osteosarcoma
• Others

By Age Group * Pediatric

• Adults

By Type * Branded

• Generic

By Therapy * Targeted Therapy

• Immunotherapy
• Chemotherapy
• Others

By Route of Administration * Oral

• Parenteral

By Distribution Channel * Hospital Pharmacies

• Drug stores & retail pharmacies
• Online Pharmacies

By Region * North America (By Drug, Drug Class, Disease Indication, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Drug, Drug Class, Disease Indication, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug, Drug Class, Disease Indication, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug, Drug Class, Disease Indication, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug, Drug Class, Disease Indication, Age Group, Type, Therapy, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Sarcoma, By Key Countries /Regions, 2025
• 4.2. New Product Launches, By Key Players
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
• 4.4. Regulatory & Reimbursement Scenario, By Key Countries/Regions
• 4.5. Pipeline Analysis, By Key Players

5. Global Sarcoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug
  • 5.1.1. Imatinib
  • 5.1.2. Pazopanib
  • 5.1.3. Ripretinib
  • 5.1.4. Nirogacestat
  • 5.1.5. Trabectedin
  • 5.1.6. Avapritinib
  • 5.1.7. Others
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. Cytotoxic Chemotherapy
  • 5.2.2. Tyrosine Kinase Inhibitors (TKIs)
  • 5.2.3. Gamma Secretase Inhibitors
  • 5.2.4. Immune Checkpoint Inhibitors
  • 5.2.5. Cell Therapies
  • 5.2.6. Epigenetic/EZH2 Inhibitors
  • 5.2.7. Others
• 5.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.3.1. GIST
  • 5.3.2. Leiomyosarcoma
  • 5.3.3. Liposarcoma
  • 5.3.4. Synovial Sarcoma
  • 5.3.5. Desmoid Tumors
  • 5.3.6. Osteosarcoma
  • 5.3.7. Others
• 5.4. Market Analysis, Insights and Forecast - By Age Group
  • 5.4.1. Pediatric
  • 5.4.2. Adults
• 5.5. Market Analysis, Insights and Forecast - By Type
  • 5.5.1. Branded
  • 5.5.2. Generic
• 5.6. Market Analysis, Insights and Forecast - By Therapy
  • 5.6.1. Targeted therapy
  • 5.6.2. Immunotherapy
  • 5.6.3. Chemotherapy
  • 5.6.4. Others
• 5.7. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.7.1. Oral
  • 5.7.2. Parenteral
• 5.8. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.8.1. Hospital Pharmacies
  • 5.8.2. Drug Stores & Retail Pharmacies
  • 5.8.3. Online Pharmacies
• 5.9. Market Analysis, Insights and Forecast - Region
  • 5.9.1. North America
  • 5.9.2. Europe
  • 5.9.3. Asia Pacific
  • 5.9.4. Latin America
  • 5.9.5. Middle East & Africa

6. North America Sarcoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug
  • 6.1.1. Imatinib
  • 6.1.2. Pazopanib
  • 6.1.3. Ripretinib
  • 6.1.4. Nirogacestat
  • 6.1.5. Trabectedin
  • 6.1.6. Avapritinib
  • 6.1.7. Others
• 6.2. Market Analysis, Insights and Forecast - By Drug Class
  • 6.2.1. Cytotoxic Chemotherapy
  • 6.2.2. Tyrosine Kinase Inhibitors (TKIs)
  • 6.2.3. Gamma Secretase Inhibitors
  • 6.2.4. Immune Checkpoint Inhibitors
  • 6.2.5. Cell Therapies
  • 6.2.6. Epigenetic/EZH2 Inhibitors
  • 6.2.7. Others
• 6.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.3.1. GIST
  • 6.3.2. Leiomyosarcoma
  • 6.3.3. Liposarcoma
  • 6.3.4. Synovial Sarcoma
  • 6.3.5. Desmoid Tumors
  • 6.3.6. Osteosarcoma
  • 6.3.7. Others
• 6.4. Market Analysis, Insights and Forecast - By Age Group
  • 6.4.1. Pediatric
  • 6.4.2. Adults
• 6.5. Market Analysis, Insights and Forecast - By Type
  • 6.5.1. Branded
  • 6.5.2. Generic
• 6.6. Market Analysis, Insights and Forecast - By Therapy
  • 6.6.1. Targeted therapy
  • 6.6.2. Immunotherapy
  • 6.6.3. Chemotherapy
  • 6.6.4. Others
• 6.7. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.7.1. Oral
  • 6.7.2. Parenteral
• 6.8. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.8.1. Hospital Pharmacies
  • 6.8.2. Drug Stores & Retail Pharmacies
  • 6.8.3. Online Pharmacies
• 6.9. Market Analysis, Insights and Forecast - By Country
  • 6.9.1. U.S.
  • 6.9.2. Canada

7. Europe Sarcoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug
  • 7.1.1. Imatinib
  • 7.1.2. Pazopanib
  • 7.1.3. Ripretinib
  • 7.1.4. Nirogacestat
  • 7.1.5. Trabectedin
  • 7.1.6. Avapritinib
  • 7.1.7. Others
• 7.2. Market Analysis, Insights and Forecast - By Drug Class
  • 7.2.1. Cytotoxic Chemotherapy
  • 7.2.2. Tyrosine Kinase Inhibitors (TKIs)
  • 7.2.3. Gamma Secretase Inhibitors
  • 7.2.4. Immune Checkpoint Inhibitors
  • 7.2.5. Cell Therapies
  • 7.2.6. Epigenetic/EZH2 Inhibitors
  • 7.2.7. Others
• 7.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.3.1. GIST
  • 7.3.2. Leiomyosarcoma
  • 7.3.3. Liposarcoma
  • 7.3.4. Synovial Sarcoma
  • 7.3.5. Desmoid Tumors
  • 7.3.6. Osteosarcoma
  • 7.3.7. Others
• 7.4. Market Analysis, Insights and Forecast - By Age Group
  • 7.4.1. Pediatric
  • 7.4.2. Adults
• 7.5. Market Analysis, Insights and Forecast - By Type
  • 7.5.1. Branded
  • 7.5.2. Generic
• 7.6. Market Analysis, Insights and Forecast - By Therapy
  • 7.6.1. Targeted therapy
  • 7.6.2. Immunotherapy
  • 7.6.3. Chemotherapy
  • 7.6.4. Others
• 7.7. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.7.1. Oral
  • 7.7.2. Parenteral
• 7.8. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.8.1. Hospital Pharmacies
  • 7.8.2. Drug Stores & Retail Pharmacies
  • 7.8.3. Online Pharmacies
• 7.9. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.9.1. U.K.
  • 7.9.2. Germany
  • 7.9.3. France
  • 7.9.4. Italy
  • 7.9.5. Spain
  • 7.9.6. Scandinavia
  • 7.9.7. Rest of Europe

8. Asia Pacific Sarcoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug
  • 8.1.1. Imatinib
  • 8.1.2. Pazopanib
  • 8.1.3. Ripretinib
  • 8.1.4. Nirogacestat
  • 8.1.5. Trabectedin
  • 8.1.6. Avapritinib
  • 8.1.7. Others
• 8.2. Market Analysis, Insights and Forecast - By Drug Class
  • 8.2.1. Cytotoxic Chemotherapy
  • 8.2.2. Tyrosine Kinase Inhibitors (TKIs)
  • 8.2.3. Gamma Secretase Inhibitors
  • 8.2.4. Immune Checkpoint Inhibitors
  • 8.2.5. Cell Therapies
  • 8.2.6. Epigenetic/EZH2 Inhibitors
  • 8.2.7. Others
• 8.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.3.1. GIST
  • 8.3.2. Leiomyosarcoma
  • 8.3.3. Liposarcoma
  • 8.3.4. Synovial Sarcoma
  • 8.3.5. Desmoid Tumors
  • 8.3.6. Osteosarcoma
  • 8.3.7. Others
• 8.4. Market Analysis, Insights and Forecast - By Age Group
  • 8.4.1. Pediatric
  • 8.4.2. Adults
• 8.5. Market Analysis, Insights and Forecast - By Type
  • 8.5.1. Branded
  • 8.5.2. Generic
• 8.6. Market Analysis, Insights and Forecast - By Therapy
  • 8.6.1. Targeted therapy
  • 8.6.2. Immunotherapy
  • 8.6.3. Chemotherapy
  • 8.6.4. Others
• 8.7. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.7.1. Oral
  • 8.7.2. Parenteral
• 8.8. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.8.1. Hospital Pharmacies
  • 8.8.2. Drug Stores & Retail Pharmacies
  • 8.8.3. Online Pharmacies
• 8.9. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.9.1. China
  • 8.9.2. Japan
  • 8.9.3. India
  • 8.9.4. Southeast Asia
  • 8.9.5. Australia
  • 8.9.6. Rest of Asia Pacific

9. Latin America Sarcoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug
  • 9.1.1. Imatinib
  • 9.1.2. Pazopanib
  • 9.1.3. Ripretinib
  • 9.1.4. Nirogacestat
  • 9.1.5. Trabectedin
  • 9.1.6. Avapritinib
  • 9.1.7. Others
• 9.2. Market Analysis, Insights and Forecast - By Drug Class
  • 9.2.1. Cytotoxic Chemotherapy
  • 9.2.2. Tyrosine Kinase Inhibitors (TKIs)
  • 9.2.3. Gamma Secretase Inhibitors
  • 9.2.4. Immune Checkpoint Inhibitors
  • 9.2.5. Cell Therapies
  • 9.2.6. Epigenetic/EZH2 Inhibitors
  • 9.2.7. Others
• 9.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.3.1. GIST
  • 9.3.2. Leiomyosarcoma
  • 9.3.3. Liposarcoma
  • 9.3.4. Synovial Sarcoma
  • 9.3.5. Desmoid Tumors
  • 9.3.6. Osteosarcoma
  • 9.3.7. Others
• 9.4. Market Analysis, Insights and Forecast - By Age Group
  • 9.4.1. Pediatric
  • 9.4.2. Adults
• 9.5. Market Analysis, Insights and Forecast - By Type
  • 9.5.1. Branded
  • 9.5.2. Generic
• 9.6. Market Analysis, Insights and Forecast - By Therapy
  • 9.6.1. Targeted therapy
  • 9.6.2. Immunotherapy
  • 9.6.3. Chemotherapy
  • 9.6.4. Others
• 9.7. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.7.1. Oral
  • 9.7.2. Parenteral
• 9.8. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.8.1. Hospital Pharmacies
  • 9.8.2. Drug Stores & Retail Pharmacies
  • 9.8.3. Online Pharmacies
• 9.9. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.9.1. Brazil
  • 9.9.2. Mexico
  • 9.9.3. Rest of Latin America

10. Middle East & Africa Sarcoma Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug
  • 10.1.1. Imatinib
  • 10.1.2. Pazopanib
  • 10.1.3. Ripretinib
  • 10.1.4. Nirogacestat
  • 10.1.5. Trabectedin
  • 10.1.6. Avapritinib
  • 10.1.7. Others
• 10.2. Market Analysis, Insights and Forecast - By Drug Class
  • 10.2.1. Cytotoxic Chemotherapy
  • 10.2.2. Tyrosine Kinase Inhibitors (TKIs)
  • 10.2.3. Gamma Secretase Inhibitors
  • 10.2.4. Immune Checkpoint Inhibitors
  • 10.2.5. Cell Therapies
  • 10.2.6. Epigenetic/EZH2 Inhibitors
  • 10.2.7. Others
• 10.3. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.3.1. GIST
  • 10.3.2. Leiomyosarcoma
  • 10.3.3. Liposarcoma
  • 10.3.4. Synovial Sarcoma
  • 10.3.5. Desmoid Tumors
  • 10.3.6. Osteosarcoma
  • 10.3.7. Others
• 10.4. Market Analysis, Insights and Forecast - By Age Group
  • 10.4.1. Pediatric
  • 10.4.2. Adults
• 10.5. Market Analysis, Insights and Forecast - By Type
  • 10.5.1. Branded
  • 10.5.2. Generic
• 10.6. Market Analysis, Insights and Forecast - By Therapy
  • 10.6.1. Targeted therapy
  • 10.6.2. Immunotherapy
  • 10.6.3. Chemotherapy
  • 10.6.4. Others
• 10.7. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.7.1. Oral
  • 10.7.2. Parenteral
• 10.8. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.8.1. Hospital Pharmacies
  • 10.8.2. Drug Stores & Retail Pharmacies
  • 10.8.3. Online Pharmacies
• 10.9. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.9.1. GCC
  • 10.9.2. South Africa
  • 10.9.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Novartis AG
  • 11.2.2. Pfizer Inc.
  • 11.2.3. Deciphera Pharmaceuticals, LLC
  • 11.2.4. Blueprint Medicines Corporation
  • 11.2.5. Eisai Co., Ltd.
  • 11.2.6. PharmaMar, S.A.
  • 11.2.7. Johnson & Johnson
  • 11.2.8. Adaptimmune Therapeutics plc
  • 11.2.9. Aadi Bioscience, Inc.
  • 11.2.10. Genentech, Inc.